In the past decade, we have experienced an explosion of new information aboutcancer therapeutic targets. Many of the targets have been validated by the discovery and approval of new medicines which have been approved for the treatment of cancer. On the heels of these successes, innumerable new targets and newpotential therapeutics are being developed by many different groups includinggovernment agencies, pharmaceutical companies, biotechnology companies, academic institutions, and individual investigators. Understanding the expanding "universe" of cancer therapies is therefore becoming impossible and no single source exists which serves as a reference for the involved parties. Further, theinterested parties have vastly different areas of expertise, from focused laboratory based science, to clinical research, to corporate and regulatory oversight.The text would be updated every two years, more often depending on pace of change, interest and sales. While useful online, this reference book would likely be kept in hard copy as well. INDICE: Anti-angiogenic Targets HER2/EGFR Targets Nuclear Receptors Hormone receptors Heme surface markers Other surface markers Bcr/abl Proteosome inhibitors PPAR gamma PARP Methylation Immune therapies Cytokines mTOR wynt/apc IGF, survival, PI3K, AKT
- ISBN: 978-1-4419-0716-5
- Editorial: Springer
- Encuadernacion: Cartoné
- Fecha Publicación: 03/06/2013
- Nº Volúmenes: 1
- Idioma: Inglés